Care Bundle Containing Chlorhexidine Dressing on Port Catheter and Central Venous Catheters
NCT ID: NCT06720064
Last Updated: 2024-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2024-05-07
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
These infections are infections that develop after admission to the hospital and are not in the incubation period at the time of admission, or although they usually develop in the hospital 48-72 hours after hospitalization, they can sometimes appear after discharge. Central line-associated bloodstream infections significantly increase morbidity and mortality. In this context, the effect of using a care bundle containing chlorhexidine dressing on port catheter and central venous catheter-related bloodstream infections in pediatric cancer patients was examined.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypotheses of the Research H1: Care bundle approach including chlorhexidine dressing in pediatric cancer patients reduces port catheter and central venous catheter-related bloodstream infections.
H2: Care bundle approach including chlorhexidine dressing in pediatric cancer patients reduces port catheter and central venous catheter-related complications.
Randomization A stratified randomization scheme was used to distribute the sample into groups. Stratification randomization was made according to port catheter stay duration, age group, hematological/oncological cancer type and hematopoietic stem cell transplantation unit / pediatric hematology and oncology clinic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Standard care bundle approach; The following materials will be used by nurses while performing their care in accordance with the relevant care bundle and checklist;
* Transparent catheter cover (3M™ IV-Tegaderm™) (Control group)
* Needle-free interventional apparatus (BD Qsyte split septum™),
* Prefilled flush syringe (BD PosiFlush™)
* Alcohol swab (alcohol cloth),
* Solupred Swab (3M™), (will be used to clean the dressing area)
No interventions assigned to this group
Care bundle approach with Chlorhexidine Dressing
Care bundle approach with Chlorhexidine Dressing The following materials will be used by nurses while performing their care in accordance with the relevant care bundle and checklist;
* Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™) (Study group)
* Needle-free interventional apparatus (BD Qsyte split septum™),
* Prefilled flush syringe (BD PosiFlush™)
* Alcohol swab (alcohol cloth),
* Solupred Swab (3M™), (will be used to clean the dressing area)
Chlorhexidine Dressing
Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chlorhexidine Dressing
Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The child has a diagnosis of hematological or oncological cancer
* The child's age range is between 1 and 17
* Having a port catheter inserted and no early complications have occurred
* The child agrees to participate in the study voluntarily
* The parent agrees to participate in the study voluntarily
* Obtaining the consent form from the child and parent
* He has been in the hospital for more than 48 hours
Exclusion Criteria
1 Year
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Afyonkarahisar Health Science University
UNKNOWN
Dokuz Eylul University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gülçin Özalp Gerçeker
Assoc. Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gulcin Ozalp Gerceker, Assoc. Prof.
Role: PRINCIPAL_INVESTIGATOR
Dokuz Eylul University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gülçin Özalp Gerçeker
Izmir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gülçin Ö Gerçeker
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
carebundle
Identifier Type: -
Identifier Source: org_study_id